Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lanthanum hydroxide is an inorganic compound (La(OH)₃) investigated as a **phosphate binder** for the control of hyperphosphatemia, primarily in the context of chronic kidney disease (CKD) and renal failure. It works by binding dietary phosphate in the gastrointestinal tract, reducing absorption and lowering serum phosphate levels. Recent animal studies indicate additional pharmacological effects, such as protecting renal function, postponing development of renal failure, and mitigating vascular calcification by **inhibiting the nuclear factor kappa-B (NF-κB) signaling pathway** and the **receptor activator for nuclear factor-κB ligand/osteoprotegerin (RANKL/OPG) signaling cascade**. Compared to other phosphate binders, lanthanum hydroxide is notable for its effectiveness in reducing blood phosphate, and it does not affect fat-soluble vitamin absorption.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lanthanum hydroxide.